Distraction or Destruction?: What’s New/Next in the Industry

Our next panel, “Distraction or Destruction?: What’s New/Next in the Industry” featured Niquette Hunt, President & CEO of Candesant Biomedical, Mark Plinio, CCO of Evelo Biosciences, Luis Peña, President & CEO of Evommune, September Riharb, SVP Marketing of Jeune, Inc., Paula Brown Stafford, President & CEO of Novan, Inc., Tim Holt, President & CEO of R2 Technologies, Inc., Ron Menezes, President and CEO of Sientra, Inc., and Denise Dajles, SVP, R&D, Regulation & Clinical of Sientra, Inc. The panel was moderated by Cantor’s Louise Chen.

• Evelo walked through its highly differentiated small intestinal axis (SINTAX) medicines platform, which is nearing key catalysts next year in psoriasis and atopic dermatitis

• Novan remains on-track for NDA submission of its lead pipeline candidate, berdazimer gel, 10.3% (SB206) around the end of 2022, for the treatment of molluscum contagiosum

#Cantor #Cantorfitzgerald #Cantorhealthcare #Cantorconferenceseries #Dermatology #Opthalmology #Medtech #Diagnostic